Clinical Trial Update: A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two dose regimens of risankizumab subcutaneous in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Generalized Pustular Psoriasis
• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-06